← Browse by Condition

Medical Condition

multiple myeloma

Total Trials

51

Recruiting Now

51

Trial Phases

Phase 2, Phase 1, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for multiple myeloma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — multiple myeloma Clinical Trials

How many clinical trials are currently recruiting for multiple myeloma?

ClinicalMetric currently tracks 51 actively recruiting clinical trials for multiple myeloma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 51. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for multiple myeloma?

multiple myeloma research spans Phase 1 (13 trials), Phase 2 (15 trials), Phase 3 (6 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a multiple myeloma clinical trial?

Eligibility criteria for multiple myeloma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

13

Phase 2

15

Phase 3

6

Top Sponsors

Washington University School of Medicine 3 trials

Bristol-Myers Squibb 3 trials

M.D. Anderson Cancer Center 2 trials

Pfizer 2 trials

Memorial Sloan Kettering Cancer Center 2 trials

Recruiting Clinical Trials

NCT02693535 Phase 2

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

United States, Puert...

American Society of Clinical O...

NCT06581640 Phase 2

Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma

The First Affiliated Hospital ...

NCT07333261 Phase 1

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

NCT07200102 Phase 1

Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

Washington University School o...

NCT06700395 Phase 1

A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma

Chia Tai Tianqing Pharmaceutic...

Family Study of Lymphoproliferative Disorders

NCT05828511 Phase 1, Phase 2

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

United States, Franc...

Regeneron Pharmaceuticals

NCT06207799 Phase 2

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

M.D. Anderson Cancer Center

A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea

Bristol-Myers Squibb

Universal CAR-T Cell Therapy for MM

Bioray Laboratories

Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients

Haikou Affiliated Hospital of ...

NCT06152575 Phase 3

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

United States, Argen...

PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.

Centre Leon Berard

NCT07227311 Phase 2

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

United States, Franc...

GlaxoSmithKline

Discontinuation Study

University College Cork

Prehabilitation Feasibility Among Older Adults Undergoing Transplantation

Noha Mohamed Sharafeldin

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

Memorial Sloan Kettering Cance...

NCT06132711 Phase 1, Phase 2

Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma

Xuzhou Medical University

NCT06799026 Phase 1

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

NCT07490613 Phase 1

A Phase I Study of SHR-3836 in Patients With Multiple Myeloma

Shanghai Hengrui Pharmaceutica...

NCT06407947 EARLY_Phase 1

Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma

Shanghai Changzheng Hospital

NCT06500884 Phase 2

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

United States, Brazi...

Janssen Research & Development...

NCT07105059 Phase 1

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

Memorial Sloan Kettering Cance...

Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD

Sir Mortimer B. Davis - Jewish...

LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study

University of Alberta

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

United States, Germa...

Bristol-Myers Squibb

NCT06623630 Phase 1

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

Washington University School o...

PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma

NCT05846880 EARLY_Phase 1

VitD3 Supplementation in Patients With Multiple Myeloma

Amany Keruakous, MD, MS.

Evaluation of a PREHABilitation Protocol Using Adapted Physical Activity (APA) for Multiple Myeloma Patients Eligible for Intensive Autologous Stem Cell Transplantation Treatment

Centre Hospitalier Henri Duffa...

Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma

Center for International Blood...

NCT06048250 Phase 1

Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma

City of Hope Medical Center

Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment

Fondazione IRCCS Policlinico S...

Myeloma Novel Drug Discovery Ver 1.2

Institute of Cancer Research, ...

NCT05344833 Phase 2

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

University of Illinois at Chic...

NCT07555938 Phase 3

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

United States, Austr...

Hoffmann-La Roche

European Myeloma Network (EMN) Sample Project

Australia, Austria, ...

European Myeloma Network B.V.

Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry

University of Alabama at Birmi...

An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers

Washington University School o...

NCT05372354 Phase 1, Phase 2

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

United States, Canad...

Bristol-Myers Squibb

NCT06461988 Phase 2

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

Stanford University

NCT05776979 Phase 2

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

M.D. Anderson Cancer Center

NCT06932562 Phase 3

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

Australia, Austria, ...

European Myeloma Network B.V.

NCT06910124 Phase 2

Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

Dickran Kazandjian, MD

NCT06520176 Phase 3

Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

The Affiliated People's Hospit...

NCT05020236 Phase 3

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

United States, Argen...

NCT04513639 Phase 2, Phase 3

The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

Oslo University Hospital

NCT05145400 Phase 2

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

UNC Lineberger Comprehensive C...

Digital Support for Multiple Myeloma Quality of Life

FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease

University of Miami

NCT06505369 Phase 2

Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

Denmark, Estonia, No...

North Estonia Medical Centre

Related Conditions

lymphoma (3) cancer (3) lymphoma non hodgkin (2) mgus (2) smoldering multiple myeloma (2) plasma cell leukemia (2) advanced solid tumors (1) relapsed refractory (1) leukemia lymphocytic chronic b cell (1) lymphoma b cell (1) monoclonal b cell lymphocytosis (1) post transplant mrd guided maintenance therapy (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology